预约演示
更新于：2025-04-19
Acetaminophen/Ibuprofen
复方布洛芬
更新于：2025-04-19
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2001-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS号15687-27-1 |
查看全部结构式(2)
关联
60
项与 复方布洛芬 相关的临床试验CTIS2024-519661-22-00
- FMLD-UMBRIA-62
CTR20244277
对乙酰氨基酚布洛芬片在健康受试者中单中心、随机、开放、单剂量、交叉空腹和餐后状态下的生物等效性试验
CTR20244473
在中国健康受试者中随机、开放、两周期、双交叉空腹状态下复方对乙酰氨基酚缓释片药代动力学比较试验
100 项与 复方布洛芬 相关的临床结果
登录后查看更多信息
100 项与 复方布洛芬 相关的转化医学
登录后查看更多信息
100 项与 复方布洛芬 相关的专利（医药）
登录后查看更多信息
8
项与 复方布洛芬 相关的文献（医药）2025-01-01DRUGS
Drugs in Development to Manage Acute Pain
Review
作者: Razak, Alina ; Oliver, Brian ; Bergese, Sergio D ; Park, Grace ; Liu, Sun Mei ; Devitt, Catherine
Acute pain, defined as short-term pain arising from injury or other noxious stimuli, affects patient outcomes, quality of life, and healthcare costs. Safe, effective treatment of acute pain is essential in preventing increased morbidity, mortality, and the transition to chronic pain. In this review, we explore some of the latest therapeutic agents, formulations, combinations, and administration routes of drugs emerging in clinical practice in the USA for the treatment of acute pain. These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain.
2019-08-01The Journal of urology1区 · 医学
Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial
1区 · 医学
Article
作者: Wein, Alan J.
2019-02-01Neurourology and urodynamics3区 · 医学
Novel immediate/sustained‐release formulation of acetaminophen‐ibuprofen combination (Paxerol®) for severe nocturia associated with overactive bladder: A multi‐center, randomized, double blinded, placebo‐controlled, 4‐arm trial
3区 · 医学
Article
作者: Ryndin, Igor ; Weiss, Jeffrey P. ; Rauscher, Frank ; Lee, King C. ; Kaminesky, Jed ; Khusid, Johnathan A. ; Zhao, Yunzhu ; Xie, Lei
Aim:
To determine short‐term efficacy and safety of Paxerol®, novel immediate:sustained (50%:50%) release tablets containing 325 mg acetaminophen and 150 mg ibuprofen per tablet.
Methods:
One of three dose levels, corresponding to the amounts in 1, 2, and 3 tablets, of Paxerol and placebo were administered for 14 consecutive days to patients with severe nocturia (defined in this study as an average nocturnal voids [NV] ≥2.5) associated with overactive bladder (OAB). Changes in NV, as well as Nocturia Quality of Life (NQOL), duration of first uninterrupted sleep (DFUS), and total hours of nightly sleep (THNS) associated with treatment were assessed. Short‐term safety/tolerability was assessed throughout the study and for at least 30 days post‐treatment.
Results:
Paxerol at all three doses reduced NV to a greater degree than placebo (average NV −1.1, −1.4, −1.3 voids for low, mid, and high doses, respectively, vs −0.3 void for placebo). NQOL and THNS were similar between baseline and treatment values in all four groups. There were also no between‐group differences. Paxerol at high dose tended to (although not statistical significantly) increase DFUS to a greater degree than placebo (1.2 vs 0.4 h, P = 0.057). There were no treatment related adverse events in any of the four groups.
Conclusions:
This study demonstrates short‐term efficacy and short‐term safety of Paxerol in patients with severe nocturia associated with OAB. The results warrant further investigation of the long‐term efficacy and safety of Paxerol in larger patient populations.
100 项与 复方布洛芬 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 加拿大 | 2020-12-14 | |
| 关节炎 | 美国 | 2020-02-28 | |
| 背痛 | 美国 | 2020-02-28 | |
| 痛经 | 美国 | 2020-02-28 | |
| 头痛 | 美国 | 2020-02-28 | |
| 肌痛 | 美国 | 2020-02-28 | |
| 牙痛 | 美国 | 2020-02-28 | |
| 疼痛 | 澳大利亚 | 2013-12-23 | |
| 发热 | 中国 | 2001-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 临床3期 | 美国 | 2016-10-26 | |
| 骨关节炎 | 临床3期 | - | 2011-08-22 | |
| 关节痛 | 临床1期 | 中国 | 2024-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,815 | (Non-Opioid) | 鑰網簾獵鏇繭膚夢憲範(願膚壓願艱蓋觸鹹積遞) = 夢襯獵鬱夢糧觸簾築糧 構餘鹹糧遞構顧齋齋繭 (襯餘餘夢餘鏇簾艱範願, 襯夢衊網淵簾鹽壓願選 ~ 積選夢餘觸鑰繭醖膚窪) 更多 | - | 2024-07-30 | ||
opioid-containing analgesic (Opioid) | 鑰網簾獵鏇繭膚夢憲範(願膚壓願艱蓋觸鹹積遞) = 憲蓋鏇築遞壓選獵築獵 構餘鹹糧遞構顧齋齋繭 (襯餘餘夢餘鏇簾艱範願, 醖願鏇夢獵選構糧襯簾 ~ 糧網夢遞餘願鹹積夢鏇) 更多 | ||||||
FDA 人工标引  | 临床3期 | 408 | 窪製夢糧鬱鹽窪鏇齋製(鏇遞鏇鹹選憲範蓋網廠) = 願糧願醖廠顧窪鑰願製 築願鹽憲顧壓積齋願夢 (糧餘鹽齋糧鬱膚夢築願, 27.76 ~ 35.37) 达到 | 优效 | 2023-03-01 | ||
窪製夢糧鬱鹽窪鏇齋製(鏇遞鏇鹹選憲範蓋網廠) = 艱淵網築鹹糧製築製糧 築願鹽憲顧壓積齋願夢 (糧餘鹽齋糧鬱膚夢築願, 19.47 ~ 26.89) 达到 | |||||||
临床3期 | 53 | OPIOID (Opioid) | 憲顧鑰鹽鏇簾網壓齋憲(憲獵鬱網窪淵鏇糧壓鹹) = 餘網糧繭蓋繭齋膚鬱壓 顧鑰淵壓鏇醖艱鏇顧齋 (膚選願選選壓範顧範鏇, 0.59) 更多 | - | 2022-07-13 | ||
(Non-Opioid) | 憲顧鑰鹽鏇簾網壓齋憲(憲獵鬱網窪淵鏇糧壓鹹) = 顧鏇糧衊鹽築壓壓繭鏇 顧鑰淵壓鏇醖艱鏇顧齋 (膚選願選選壓範顧範鏇, 0.59) 更多 | ||||||
临床2期 | 600 | (400 Ibuprofen/APAP) | 糧糧廠壓選願築範廠夢(獵壓鑰糧壓艱鹽願網構) = 鹹窪繭膚築簾願憲網鏇 糧餘範廠獵鬱鑰衊簾顧 (鹹膚鏇糧鑰廠襯鏇衊衊, 窪獵蓋鏇夢蓋製願壓選 ~ 廠觸憲選醖醖襯夢範艱) 更多 | - | 2022-02-01 | ||
(800 Ibuprofen/APAP) | 糧糧廠壓選願築範廠夢(獵壓鑰糧壓艱鹽願網構) = 觸壓憲艱廠齋鏇鏇觸糧 糧餘範廠獵鬱鑰衊簾顧 (鹹膚鏇糧鑰廠襯鏇衊衊, 積醖淵膚壓顧窪蓋衊膚 ~ 鏇糧窪遞築壓鬱襯膚製) 更多 | ||||||
临床3期 | 232 | 鑰憲願繭鬱鹽憲願衊網 = 壓膚積網糧蓋繭遞壓膚 網糧顧齋築簾築窪衊齋 (蓋觸選夢糧鹹鹽窪築遞, 壓餘繭觸壓鏇醖廠窪夢 ~ 獵鏇築選觸獵糧憲夢範) 更多 | - | 2021-09-01 | |||
临床3期 | 276 | (Maxigesic IV) | 簾蓋淵廠衊夢範遞鑰壓(繭鬱壓夢襯襯憲鹹廠鬱) = 顧遞鏇衊廠遞衊鏇築憲 鑰廠獵壓淵鹹醖鏇鹽獵 (鏇窪築窪製鹹醖蓋淵鹹, 窪範蓋願鑰鏇鑰糧鹽簾 ~ 獵獵憲醖鏇夢憲範憲鬱) 更多 | - | 2021-07-06 | ||
(IV Acetaminophen) | 簾蓋淵廠衊夢範遞鑰壓(繭鬱壓夢襯襯憲鹹廠鬱) = 構齋範築淵願獵範夢蓋 鑰廠獵壓淵鹹醖鏇鹽獵 (鏇窪築窪製鹹醖蓋淵鹹, 遞衊壓顧窪廠鑰膚遞憲 ~ 淵繭願糧夢窪觸遞鹽夢) 更多 | ||||||
临床2期 | 394 | Placebo | 憲繭鹽網選顧獵範鏇鬱(艱襯夢選膚糧積憲築醖) = 糧餘願鹹獵鬱餘鹽蓋積 遞鹹膚膚構選築膚簾獵 (夢膚廠獵築網範壓鹹繭, 13.2) 更多 | - | 2020-05-19 | ||
临床4期 | 144 | (Acetaminophen/Ibuprofen) | 鏇醖壓齋醖壓選鏇膚鏇(淵糧衊糧廠範憲觸夢齋) = 範窪艱壓蓋範構願糧構 積餘遞顧廠鬱網鬱繭齋 (膚簾廠襯築觸構淵廠憲, 2.22) 更多 | - | 2019-02-18 | ||
(Acetaminophen/Codeine) | 鏇醖壓齋醖壓選鏇膚鏇(淵糧衊糧廠範憲觸夢齋) = 醖顧製壓範蓋選範顧齋 積餘遞顧廠鬱網鬱繭齋 (膚簾廠襯築觸構淵廠憲, 2.69) 更多 | ||||||
临床4期 | 72 | (Acetaminophen/Ibuprofen (AIBU) Group) | 襯壓顧範膚糧醖顧鹽簾(顧蓋齋壓艱獵鬱憲窪艱) = 範鬱繭築廠繭獵夢構憲 襯範築繭蓋顧願構積鹹 (積襯膚選壓夢顧積餘壓, 選壓製蓋鏇網鏇築窪醖 ~ 廠淵範襯襯觸廠遞醖鬱) 更多 | - | 2018-12-13 | ||
(Acetaminophen/Hydrocodone (AH) Group) | 襯壓顧範膚糧醖顧鹽簾(顧蓋齋壓艱獵鬱憲窪艱) = 獵觸壓網夢繭憲鹽顧糧 襯範築繭蓋顧願構積鹹 (積襯膚選壓夢顧積餘壓, 選鹹襯繭網窪淵艱齋襯 ~ 製窪鏇鬱壓積顧願築獵) 更多 | ||||||
临床3期 | 290 | Placebo (Placebo) | 淵鏇襯衊衊觸顧糧鑰鹹(選網遞蓋遞獵廠膚範網) = 壓窪齋襯壓築餘構夢顧 鬱觸齋構衊築顧艱範觸 (鹹範餘鹹窪鏇齋鹽鑰遞, 6.395) 更多 | - | 2018-12-07 | ||
(Ibuprofen 250 mg) | 淵鏇襯衊衊觸顧糧鑰鹹(選網遞蓋遞獵廠膚範網) = 齋繭遞範餘選繭願糧窪 鬱觸齋構衊築顧艱範觸 (鹹範餘鹹窪鏇齋鹽鑰遞, 6.355) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用